These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 32820669

  • 1. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG, Leegwater E, Wilms EB, van Nieuwkoop C.
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [Abstract] [Full Text] [Related]

  • 2. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
    Smith JR, Rybak JM, Claeys KC.
    Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
    [Abstract] [Full Text] [Related]

  • 3. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
    Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A.
    J Antimicrob Chemother; 2017 Sep 01; 72(9):2616-2626. PubMed ID: 28575389
    [Abstract] [Full Text] [Related]

  • 4. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
    Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A.
    Antimicrob Agents Chemother; 2016 Oct 01; 60(10):6234-43. PubMed ID: 27503659
    [Abstract] [Full Text] [Related]

  • 5. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H, Ouweini AEL, Chahine EB, Karaoui LR.
    Am J Health Syst Pharm; 2021 Mar 31; 78(8):674-683. PubMed ID: 33580649
    [Abstract] [Full Text] [Related]

  • 6. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
    Sellarès-Nadal J, Eremiev S, Burgos J, Almirante B.
    Expert Opin Pharmacother; 2021 Aug 31; 22(12):1521-1531. PubMed ID: 34120547
    [Abstract] [Full Text] [Related]

  • 7. Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections.
    Thakare R, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2020 Apr 31; 56(4):241-255. PubMed ID: 32309820
    [Abstract] [Full Text] [Related]

  • 8. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
    Heo YA.
    Drugs; 2021 Feb 31; 81(3):377-388. PubMed ID: 33630278
    [Abstract] [Full Text] [Related]

  • 9. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
    Bhagunde P, Zhang Z, Racine F, Carr D, Wu J, Young K, Rizk ML.
    Int J Infect Dis; 2019 Dec 31; 89():55-61. PubMed ID: 31479762
    [Abstract] [Full Text] [Related]

  • 10. The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
    Kohno S, Bando H, Yoneyama F, Kikukawa H, Kawahara K, Shirakawa M, Aoyama N, Brown M, Paschke A, Takase A.
    J Infect Chemother; 2021 Feb 31; 27(2):262-270. PubMed ID: 33191112
    [Abstract] [Full Text] [Related]

  • 11. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia.
    Chaftari AM, Dagher H, Hachem R, Jiang Y, Lamie P, Wilson Dib R, John T, Haddad A, Philip A, Alii S, Mulanovich P, Yuan Y, Chaftari P, Raad I.
    J Antimicrob Chemother; 2024 Oct 01; 79(10):2543-2553. PubMed ID: 39092963
    [Abstract] [Full Text] [Related]

  • 12. Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
    Fratoni AJ, Kois AK, Gluck JA, Nicolau DP, Kuti JL.
    J Antimicrob Chemother; 2024 May 02; 79(5):1118-1125. PubMed ID: 38517465
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS, Makieieva N, Tøndel C, Roilides E, Kelly MS, Patel M, Vaddady P, Maniar A, Zhang Y, Paschke A, Chen LF.
    J Clin Pharmacol; 2023 Dec 02; 63(12):1387-1397. PubMed ID: 37562063
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
    Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.
    Int J Antimicrob Agents; 2020 Jan 02; 55(1):105841. PubMed ID: 31704217
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.
    Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF.
    J Med Microbiol; 2020 Feb 02; 69(2):207-217. PubMed ID: 31976856
    [Abstract] [Full Text] [Related]

  • 16. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan 02; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 17. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD.
    Lancet Infect Dis; 2018 Dec 02; 18(12):1319-1328. PubMed ID: 30509675
    [Abstract] [Full Text] [Related]

  • 18. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
    Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang Z, Butterton JR.
    Antimicrob Agents Chemother; 2018 Mar 02; 62(3):. PubMed ID: 29311084
    [Abstract] [Full Text] [Related]

  • 19. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology].
    Derevianko II, Nefedova LA, Lavrinova LN.
    Urologiia; 2002 Mar 02; (3):21-5. PubMed ID: 12180053
    [Abstract] [Full Text] [Related]

  • 20. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS, Loeb M, Leto D, Brooks AA.
    Postgrad Med; 2020 Apr 02; 132(3):234-250. PubMed ID: 31608743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.